Literature DB >> 34760984

Optimization of immunotherapy for patients with hepatobiliary cancer.

Yuji Eso1, Hiroshi Seno1.   

Abstract

Entities:  

Year:  2021        PMID： 34760984      PMCID： PMC8527416          DOI： 10.21037/hbsn-21-207

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  11 in total

1.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

2.  Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma.

Authors:  Ching Ngar Wong; Petros Fessas; Kathy Dominy; Francesco A Mauri; Takahiro Kaneko; Persephone Du Parcq; Jamshid Khorashad; Pierluigi Toniutto; Robert D Goldin; Claudio Avellini; David J Pinato
Journal:  Liver Int       Date:  2020-11-16       Impact factor: 5.828

3.  Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.

Authors:  Dong-Jun Park; Pil-Soo Sung; Gil-Won Lee; Sungwoo Cho; Sung-Min Kim; Byung-Yoon Kang; Wonhee Hur; Hyun Yang; Soon-Kyu Lee; Sung-Hak Lee; Eun-Sun Jung; Chang-Ho Seo; Joseph Ahn; Ho-Joong Choi; Young-Kyoung You; Jeong-Won Jang; Si-Hyun Bae; Jong-Young Choi; Seung-Kew Yoon
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

4.  Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma.

Authors:  Celina Ang; Samuel J Klempner; Siraj M Ali; Russell Madison; Jeffrey S Ross; Eric A Severson; David Fabrizio; Aaron Goodman; Razelle Kurzrock; James Suh; Sherri Z Millis
Journal:  Oncotarget       Date:  2019-06-18

5.  NASH limits anti-tumour surveillance in immunotherapy-treated HCC.

Authors:  Dominik Pfister; Nicolás Gonzalo Núñez; Roser Pinyol; Olivier Govaere; Matthias Pinter; Marta Szydlowska; Revant Gupta; Mengjie Qiu; Aleksandra Deczkowska; Assaf Weiner; Florian Müller; Ankit Sinha; Ekaterina Friebel; Thomas Engleitner; Daniela Lenggenhager; Anja Moncsek; Danijela Heide; Kristin Stirm; Jan Kosla; Eleni Kotsiliti; Valentina Leone; Michael Dudek; Suhail Yousuf; Donato Inverso; Indrabahadur Singh; Ana Teijeiro; Florian Castet; Carla Montironi; Philipp K Haber; Dina Tiniakos; Pierre Bedossa; Simon Cockell; Ramy Younes; Michele Vacca; Fabio Marra; Jörn M Schattenberg; Michael Allison; Elisabetta Bugianesi; Vlad Ratziu; Tiziana Pressiani; Antonio D'Alessio; Nicola Personeni; Lorenza Rimassa; Ann K Daly; Bernhard Scheiner; Katharina Pomej; Martha M Kirstein; Arndt Vogel; Markus Peck-Radosavljevic; Florian Hucke; Fabian Finkelmeier; Oliver Waidmann; Jörg Trojan; Kornelius Schulze; Henning Wege; Sandra Koch; Arndt Weinmann; Marco Bueter; Fabian Rössler; Alexander Siebenhüner; Sara De Dosso; Jan-Philipp Mallm; Viktor Umansky; Manfred Jugold; Tom Luedde; Andrea Schietinger; Peter Schirmacher; Brinda Emu; Hellmut G Augustin; Adrian Billeter; Beat Müller-Stich; Hiroto Kikuchi; Dan G Duda; Fabian Kütting; Dirk-Thomas Waldschmidt; Matthias Philip Ebert; Nuh Rahbari; Henrik E Mei; Axel Ronald Schulz; Marc Ringelhan; Nisar Malek; Stephan Spahn; Michael Bitzer; Marina Ruiz de Galarreta; Amaia Lujambio; Jean-Francois Dufour; Thomas U Marron; Ahmed Kaseb; Masatoshi Kudo; Yi-Hsiang Huang; Nabil Djouder; Katharina Wolter; Lars Zender; Parice N Marche; Thomas Decaens; David J Pinato; Roland Rad; Joachim C Mertens; Achim Weber; Kristian Unger; Felix Meissner; Susanne Roth; Zuzana Macek Jilkova; Manfred Claassen; Quentin M Anstee; Ido Amit; Percy Knolle; Burkhard Becher; Josep M Llovet; Mathias Heikenwalder
Journal:  Nature       Date:  2021-03-24       Impact factor: 49.962

6.  Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma.

Authors:  Stephan Spahn; Daniel Roessler; Radu Pompilia; Gisela Gabernet; Beryl Primrose Gladstone; Marius Horger; Saskia Biskup; Magdalena Feldhahn; Sven Nahnsen; Franz J Hilke; Bernhard Scheiner; Jean-François Dufour; Enrico N De Toni; Matthias Pinter; Nisar P Malek; Michael Bitzer
Journal:  Cancers (Basel)       Date:  2020-12-18       Impact factor: 6.639

7.  Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status.

Authors:  Kota Sahara; S Ayesha Farooq; Diamantis I Tsilimigras; Katiuscha Merath; Anghela Z Paredes; Lu Wu; Rittal Mehta; J Madison Hyer; Itaru Endo; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

Review 8.  Recent Advances in Immunotherapy for Hepatocellular Carcinoma.

Authors:  Shigeharu Nakano; Yuji Eso; Hirokazu Okada; Atsushi Takai; Ken Takahashi; Hiroshi Seno
Journal:  Cancers (Basel)       Date:  2020-03-25       Impact factor: 6.639

Review 9.  Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.

Authors:  Yuji Eso; Takahiro Shimizu; Haruhiko Takeda; Atsushi Takai; Hiroyuki Marusawa
Journal:  J Gastroenterol       Date:  2019-09-07       Impact factor: 7.527
View more
  1 in total

Review 1.  Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance.

Authors:  Rongbin Ge; Zongwei Wang; Liang Cheng
Journal:  NPJ Precis Oncol       Date:  2022-05-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.